AVI BioPharma Announces Data Presentation for RNA-Based Duchenne Muscular Dystrophy Drug Candidate at the 16th International ...
October 18 2011 - 8:00AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced data presentations for eteplirsen
(the non-proprietary name assigned to AVI-4658), the Company's
investigational exon skipping therapy for the treatment of Duchenne
muscular dystrophy, at the 16th International Congress of the World
Muscle Society taking place Oct. 18-22, 2011 in Almancil, Algarve,
Portugal.
Ed Kaye, MD, Senior Vice President and Chief Medical Officer at
AVI, will present during the poster session Clinical Aspects on
Oct. 19 at 2:00 p.m. Greenwich mean time +1/6:00 a.m. Pacific time.
The presentation is titled "Comparative pharmacokinetics (PK) in
primates and humans of AVI-4658, a Phosphorodiamidate Morpholino
Oligomer (PMO) for treating DMD patients."
Dr. Kaye's presentation will be posted on the AVI BioPharma Web
site in the "Events & Presentations" section after the session
is completed.
About Eteplirsen
Eteplirsen (the nonproprietary name assigned to AVI-4658) is
AVI's lead drug candidate that is systemically delivered for the
treatment of a substantial subgroup of patients with Duchenne
muscular dystrophy (DMD). Data from clinical studies of eteplirsen
in DMD patients have demonstrated a broadly favorable safety and
tolerability profile and restoration of dystrophin protein
expression.
Eteplirsen uses AVI's novel phosphorodiamidate morpholino
oligomer (PMO)-based chemistry and proprietary exon-skipping
technology to skip exon 51 of the dystrophin gene. By skipping exon
51, eteplirsen may restore the gene's ability to make a shorter,
but still functional, form of dystrophin from mRNA. Promoting the
synthesis of a truncated dystrophin protein is intended to improve,
stabilize or significantly slow the disease process and prolong and
improve the quality of life for patients with DMD.
AVI is also developing other PMO-based exon-skipping drug
candidates intended to treat additional patients with DMD.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, the Company is able to
target a broad range of diseases and disorders through distinct
RNA-based mechanisms of action. Unlike other RNA-based approaches,
AVI's technologies can be used to directly target both messenger
RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging its highly differentiated
RNA antisense-based technology platform, AVI has built a pipeline
of potentially transformative therapeutic agents, including
eteplirsen, which is in clinical development for the treatment of
Duchenne muscular dystrophy, and multiple drug candidates that are
in clinical development for the treatment of infectious diseases.
For more information, visit www.avibio.com.
Forward-Looking Statements and
Information
In order to provide AVI's investors with an understanding of its
current results and future prospects, this press release contains
statements that are forward-looking. Any statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "will," "intends,"
"potential," "possible" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements include statements about the development of AVI's
product candidates, their efficacy, potency and utility in the
treatment of rare and infectious diseases and their potential to
treat a broad number of human diseases.
These forward-looking statements involve risks and
uncertainties, many of which are beyond AVI's control. Known risk
factors include, among others: clinical trials may not demonstrate
safety and efficacy of any of AVI's drug candidates and/or AVI's
antisense-based technology platform; and any of AVI's drug
candidates may fail in development, may not receive required
regulatory approvals, or be delayed to a point where they do not
become commercially viable.
Any of the foregoing risks could materially and adversely affect
AVI's business, results of operations and the trading price of
AVI's common stock. For a detailed description of risks and
uncertainties AVI faces, you are encouraged to review the official
corporate documents filed with the Securities and Exchange
Commission. AVI does not undertake any obligation to publicly
update its forward-looking statements based on events or
circumstances after the date hereof.
AVI Media and Investor Contact: Erin Cox Manager, Investor
Relations & Corporate Communications 425.354.5140 Email Contact
AVI Media Contact: David Schull Russo Partners 212.845.4271 Email
Contact
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024